Categories: CancerNews

From the Margins: Gilead’s Book Uniquely Captures What It’s Like To Be Marginalized by Disease

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

NORTHAMPTON, MA / ACCESSWIRE / January 30, 2024 / Gilead Sciences – The personal journeys of six people in the United Kingdom living with HIV, hepatitis C and cancer – and the challenges they face due to stigma and health inequities – come together in the form of a new, intentionally difficult-to-read book from Gilead. Entitled “From the Margins,” each person’s experience is deliberately written around the margins of the book in order to raise awareness of what it feels like to live on the periphery of society with a chronic or life-threatening disease.

“I had one foot in my cancer patient space and the other in my LGBTQ+ space,” reads an excerpt from one of the participants, named Stewart. “But there was no space where I could talk about both those things and bring them close to each other.”

Gilead teamed up with David Olusoga, a British historian and professor, to put the book together. “Throughout history and to this day, there are many people pushed to the margins of society where illness intertwines with social class, race, ethnicity, sexuality and poverty,” he says. “They shouldn’t have to take it upon themselves to overcome societies prejudices and inequalities.”

The book was published last September, and its unique format and important messages have earned significant media coverage and interest among the global patient and medical community.

The work is part of Gilead’s larger efforts to spotlight and address stigma, discrimination and other barriers to wellbeing and care; and ultimately, to improve health equity.

To read From the Margins, download a copy here.

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences

View the original press release on accesswire.com

Staff

Recent Posts

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel…

24 hours ago

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP)…

24 hours ago

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

24 hours ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”)…

24 hours ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”)…

24 hours ago

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the…

24 hours ago